尊龙凯时·(中国)人生就是搏!

Essex-Bio Group

簡繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance

2024.03.19

Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%

2024.03.18

Change of Address of Head Office and Principal Place of Business in Hong Kong

2024.01.03

Date

Title

2022-08-23

Essex Bio-Technology Announces 2022 Interim Financial Results

2022-08-15

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022」

2022-07-15

EssexBio awarded 「2021 China Pharmaceutical Industry Top 100 Series List」 and 「2022 China Pharmaceutical Brands List」

2022-05-07

Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC

2022-04-29

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting

2022-04-19

First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2022-04-08

First Patient Dosed in a Global Multi-Centre Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for treatment of Ophthalmic Diseases in the EU

2022-03-22

Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million

Essex-Bio Group

BIOTECH

HEALTHTECH

Links

Wuhan Adv.Dental Bio-Technology

UNO Medical Group

Antikor Biopharma

Mitotech S.A.

Henlius

Humacyte

Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer | Privacy Policy

粵公網安備 44049102496184號粵ICP備09032349號-1
互聯網藥品信息服務資格證書編號:（粵）-非經營性-2024-0208 深圳網站建設深圳聯雅

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT